Milic Marina, Mondini Michele, Deutsch Eric
Gustave Roussy, Université Paris-Saclay, INSERM U1030, F-94805 Villejuif, France.
Gustave Roussy, Département d'Oncologie-Radiothérapie, F-94805 Villejuif, France.
Cancers (Basel). 2022 Mar 27;14(7):1705. doi: 10.3390/cancers14071705.
Despite major research and clinical efforts, lung cancer remains the leading cause of cancer-related death. While the delivery of conformal radiotherapy and image guidance of stereotactic body radiotherapy (SBRT) have revolutionized the treatment of early-stage non-small-cell lung cancer (NSCLC), additional research is needed to elucidate underlying mechanisms of resistance and identify novel therapeutic combinations. Clinical progress relies on the successful translation of pre-clinical work, which so far has not always yielded expected results. Improved clinical modelling involves characterizing the preclinical models and selecting appropriate experimental designs that faithfully mimic precise clinical scenarios. Here, we review the current role of SBRT and the scope of pre-clinical armamentarium at our disposal to improve successful clinical translation of pre-clinical research in the radiation oncology of NSCLC.
尽管进行了大量的研究和临床努力,但肺癌仍然是癌症相关死亡的主要原因。虽然适形放疗的应用以及立体定向体部放疗(SBRT)的图像引导彻底改变了早期非小细胞肺癌(NSCLC)的治疗方式,但仍需要进一步研究以阐明耐药的潜在机制并确定新的治疗组合。临床进展依赖于临床前研究成果的成功转化,而迄今为止,其结果并非总是如预期那样。改进临床建模需要对临床前模型进行特征描述,并选择能够忠实地模拟精确临床场景的合适实验设计。在此,我们回顾了SBRT目前的作用以及我们可利用的临床前研究手段的范围,以促进NSCLC放射肿瘤学临床前研究成果的成功转化。